1 / 6

Clinical trials market research report by 2021 to 2027

The Clinical trials market research report analysis from recent past with an eye on coming years in this report that also offers projections Clinical trials industry targeted at helping in business decisions.

Kiransable07
Download Presentation

Clinical trials market research report by 2021 to 2027

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Clinical trials market trends research and projections for 2020- 2027 • A research study conducted by Global Market Insights, Inc., suggests that clinical trials marketis likely to exceed the $59.6 Billion mark by 2027, in terms of revenue; driven by high spending in R&D activities, coupled with the escalating number of drugs in various clinical trial phases. Biopharmaceutical and pharmaceutical industries have the highest R&D expenses. This factor is likely to encourage numerous pharma and biopharma companies to outsource clinical trial services • The digitization of clinical trials is aimed at performing the end-to-end digital transformation, which comes along with myriad benefits like timely progress monitoring, delivery of richer information, and accurate analysis of the results. The rising prominence of end-to-end digitization has also been driven by the rapid technological advancements to gather and manage a large amount of digital data. © 2017 Global Market Insights, Inc. USA. All Rights Reserved www.gminsights.com

  2. In terms of segmentation by phases, the phase I segment registered remuneration of $6.7 billion in 2020, owing to the mounting number of pharmaceutical & biotechnology firms that are currently initiating clinical studies for chronic diseases and other severe infections like HIV and cancer. The primary purpose of the Phase I clinical trials is to evaluate the safety of investigational new drugs to comprehend their PD and PK properties as well as detect the potential therapeutic dosage. • On the basis of study design, the global clinical trials market from the expanded access study segment is set to exhibit a CAGR of 5.3% through 2027. Expanded access study is the usage of the investigational new drug outside of the clinical trial in patients for their diagnosis, monitoring, and treatment. The segmental growth is attributable to its adoption as a potential pathway for people with serious illness to continue treatment outside the trial due to the unavailability of satisfactory therapies. • With regards to therapeutic area, the infectious disease segment will record revenue worth $5.5 billion by 2027, on account of the rising prevalence of meningitis, influenza, T.B, and other infectious diseases. Accelerating investments in the R&D of infectious diseases will further boost segmental expansion. As per the NIH (National Institutes of Health), in 2017, the funding for the R&D of infectious diseases was $5,684 million. The industry has been witnessing rapid advances in the clinical research of HCV, which has benefitted the course of development of HIV drugs. © 2017 Global Market Insights, Inc. USA. All Rights Reserved www.gminsights.com

  3. Request for a Sample Copy of this Report @ https://www.gminsights.com/request-sample/detail/5029 © 2017 Global Market Insights, Inc. USA. All Rights Reserved www.gminsights.com

  4. Regional Analysis • From a regional perspective, the Asia Pacific clinical trials industry is poised to depict a CAGR of 8.1% through 2027, as a result of the emergence of infectious diseases, mounting clinical trials, huge patient population, and rapid R&D activities. Other factors such as high government funding and the increasing number of biotechnology companies in Japan, South Korea, India, and Singapore will further impel the regional market outlook. In the wake of the COVID-19 pandemic, various firms worldwide are indulging in clinical trials for vaccine development to cater to the large patient pool as well as fast-track procedures. • Competitive Analysis • The competitive landscape of the clinical trials market comprises of companies such as Bioclinica, PAREXEL International, IQVIA, and Laboratory Corporation of America Holdings, among others. These companies are implementing varied strategies such as business expansions, M&A, and novel service launches to consolidate their market position. Request for Customization @ https://www.gminsights.com/roc/5029 © 2017 Global Market Insights, Inc. USA. All Rights Reserved www.gminsights.com

  5. Latest Research Report On Clinical Trials Market @ https://www.gminsights.com/industry-analysis/clinical-trials-market Request for sample of this research report @ https://www.gminsights.com/roc/5029 Request for customization: https://www.gminsights.com/request-sample/detail/5029 © 2017 Global Market Insights, Inc. USA. All Rights Reserved www.gminsights.com

  6. Stay In Touch You can visit us at: www.gminsights.com Thank You…! © 2017 Global Market Insights, Inc. USA. All Rights Reserved www.gminsights.com www.gminsights.com

More Related